DME therapy obtains European marketing authorization

Article

Iluvien, an intravitreal implant for the treatment of chronic diabetic macula oedema (DME) developed by Alimera Sciences, has been granted market authorization by the Austrian Agency for Health and Food Safety.

Iluvien, an intravitreal implant for the treatment of chronic diabetic macula oedema (DME) developed by Alimera Sciences, has been granted market authorization by the Austrian Agency for Health and Food Safety.

Iluvien is a sustained release intravitreal implant inserted into the back of the eye. It delivers sub-microgram levels of fluocinolone acetonide (FAc) and can be effective for up to 36 months.

The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK completed the Decentralized Regulatory Procedure (DCP) and issued a positive outcome to Iluvien. Other countries delivering a positive outcome included Austria, France, Germany, Italy, Spain and Portugal. Additional Concerned Member State (CMS) marketing authorizations are expected later this year.

Dan Myers, president and chief executive officer at Alimera Sciences, said, “We are excited to receive this marketing authorization and pleased that DME patients in Austria will have this therapy available to them. We look forward to receiving the additional expected approvals from the U.K. and other Concerned Member States as we continue on track with our commercialization plans in the EU.”

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.